Ishape 120mg Capsule contains Orlistat 120mg, a potent lipase inhibitor indicated for the management of obesity. It is prescribed as an adjunct to a reduced-calorie diet and increased physical activity in adults with a body mass index (BMI) of 30 kg/m² or greater, or those with a BMI of 27 kg/m² or greater who present with additional risk factors such as hypertension, diabetes, or dyslipidemia. Orlistat acts locally in the gastrointestinal tract by inhibiting pancreatic and gastric lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. This inhibition reduces fat absorption by approximately 30%, promoting weight loss and aiding in the improvement of obesity-related comorbidities. Ishape 120mg Capsule should be administered during or up to one hour after each main meal containing fat, with a maximum of three capsules per day. Common adverse effects include gastrointestinal symptoms such as oily spotting, flatulence with discharge, fecal urgency, and increased defecation, which are generally mild and tend to diminish over time. Patients are advised to maintain a nutritionally balanced, reduced-calorie diet with an appropriate distribution of fat intake to minimize side effects. Regular monitoring of liver function and fat-soluble vitamin levels is recommended during prolonged therapy.